Modified GRF (1-29): Research Gaps Map and Evidence Boundaries
An evidence-led Modified GRF (1-29) review focused on research gaps map, human-study limits, regulatory context and claim verification.
Review Question
This evidence review asks turning uncertainty into testable questions for Modified GRF (1-29). It is educational and does not provide dosing, treatment or purchasing advice.
Compound-Specific Context
Modified GRF (1-29) is a stabilized short-acting GHRH fragment commonly sold under the informal name CJC-1295 no DAC. It lacks the albumin-binding drug affinity complex.
Direct human outcome evidence tied unambiguously to commercial no-DAC material is sparse. Findings from CJC-1295 DAC cannot be transferred merely because sellers place both molecules under one name.
Research Gaps Map Analysis
A useful gap analysis does more than say evidence is limited. It identifies the exact missing comparison, population, duration, endpoint and safety surveillance.
The next informative study is often a molecule-specific, product-characterized, controlled trial with clinically meaningful outcomes.
This distinction matters because online summaries often merge mechanistic plausibility, acute hormone measurements and therapeutic outcomes into one claim.
Evidence Boundary Table
| Evidence layer | What this review can say |
|---|---|
| Identity | Modified GRF (1-29) is a stabilized short-acting GHRH fragment commonly sold under the informal name CJC-1295 no DAC. It lacks the albumin-binding drug affinity complex. |
| Human findings | Direct human outcome evidence tied unambiguously to commercial no-DAC material is sparse. Findings from CJC-1295 DAC cannot be transferred merely because sellers place both molecules under one name. |
| Boundary | A plausible GHRH mechanism is not proof of a particular exposure pattern, clinical benefit or long-term safety for a marketed no-DAC preparation. |
What the Evidence Supports
A plausible GHRH mechanism is not proof of a particular exposure pattern, clinical benefit or long-term safety for a marketed no-DAC preparation.
- Human, animal and cell findings must be labeled separately.
- A biomarker change is not automatically a body-composition, disease or functional outcome.
- Trial authorization is not FDA approval, and historical approval does not cover a new compounded product.
- Combination claims require evidence on the combination itself.
Source-Checking Questions
- Was the exact molecule and formulation identified?
- Was the study conducted in humans, and in which population?
- Did it measure hormones, clinical outcomes or both?
- Was follow-up adequate for the safety claim?
- Does the regulatory statement apply to this product and indication?